LGALS3BP and gastric cancer: A large body of evidence shows that high LGALS3BP expression in tissues and serum are associated with unfavourable clinical outcomes in a wide variety of malignancies, including breast, lung, ovarian, pancreatic, prostatic, liver, gastric cancers and melanoma [58].